Claims
- 1. An isolated polynucleotide comprising a sequence selected from the group consisting of:
(a) sequences provided in SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210; (b) complements of the sequences provided in SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210; (c) sequences that hybridize to a sequence provided in SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210, under moderately stringent conditions; (d) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210; (e) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210; and (f) degenerate variants of a sequence provided in SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210.
- 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) sequences encoded by a polynucleotide of claim 1; and (b) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1;(c) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1; and (d) sequences selected from the group consisting of SEQ ID NO: 181-203, 207-209 and 211-224.
- 3. An isolated antigenic epitope of a B. microti antigen comprising the amino acid sequence -X1-X2-X3-X4-X5-Ser-, wherein X1 is Glu or Gly, X2 is Ala or Thr, X3 is Gly or Val, X4 is Trp or Gly and X5 is Pro or Ser.
- 4. An isolated antigenic epitope according to claim 3 wherein X1 is Glu, X2 is Ala and X3 is Gly.
- 5. An isolated antigenic epitope according to claim 3 wherein X1 is Gly, X2 is Thr and X5 is Pro.
- 6. An isolated polypeptide comprising at least two contiguous antigenic epitopes according to claim 3.
- 7. An isolated antigenic epitope of a B. microti antigen comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:36 and 39.
- 8. An isolated polypeptide comprising at least two contiguous antigenic epitopes according to any one of claims 3 and 7.
- 9. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
- 10. A host cell transformed or transfected with an expression vector according to claim 9.
- 11. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.
- 12. A fusion protein comprising at least one polypeptide according to claim 2.
- 13. A fusion protein comprising a polypeptide having an amino acid sequence of SEQ ID NO:32.
- 14. The fusion protein of claim 13 further comprising a polypeptide having an amino acid sequence of SEQ ID NO:52.
- 15. A fusion protein comprising at least two antigenic epitopes according to any one of claims 3 and 7.
- 16. A fusion protein comprising at least one polypeptide according to any one of claims 2, 6 and 8, and at least one antigenic epitope according to any one of claims 3 and 7.
- 17. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO: 1-17, 37, 40, 42, 45, 50, 51, 91-119, 128-131, 135, 204 and 210 under moderately stringent conditions.
- 18. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:
(a) polypeptides according to any one of claims 2, 6 and 8; (b) polynucleotides according to claim 1;(c) antibodies according to claim 11; and (d) fusion proteins according to any one of claims 13, 16 and 36.
- 19. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 18.
- 20. A method for the treatment of B. microti infection in a patient, comprising administering to the patient a composition of claim 18.
- 21. A method for determining B. microti infection in a patient, comprising the steps of:
(a) obtaining a biological sample from the patient; (b) contacting the biological sample with an oligonucleotide according to claim 18;(c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and (d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining B. microti infection in the patient.
- 22. A diagnostic kit comprising at least one oligonucleotide according—to claim 18.
- 23. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.
- 24. A method for detecting B. microti infection in a patient, comprising the steps of:
(a) obtaining a biological sample from the patient; (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and (e) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining B. microti infection in the patient.
- 25. A method for detecting B. microti infection in a patient, comprising:
(a) obtaining a sample from the patient; (b) contacting the sample with at least one antigenic epitope according to any one of claims 3 and 7; and (c) detecting the presence of antibodies that bind to the antigenic epitope.
- 26. A method for detecting B. microti infection in a patient, comprising:
(a) obtaining a sample from the patient; (b) contacting the sample with at least one polypeptide according to any one of claims 2, 6 and 8; and The (c) detecting the presence of antibodies that bind to the polypeptide.
- 27. A method for detecting B. microti infection in a patient, comprising:
(a) obtaining a sample from the patient; (b) contacting the sample with at least one polypeptide according to any one of claims 2, 6 and 8, and at least one antigenic epitope according to any one of claims 3 and 7; and (c) detecting the presence of antibodies that bind to the polypeptide or antigenic epitope.
- 28. A method for detecting B. microti infection in a patient, comprising:
(a) obtaining a sample from the patient; (b) contacting the sample with a fusion protein according to any one of claims 13, 16 and 36, and (c) detecting the presence of antibodies that bind to the fusion protein.
- 29. A method of detecting B. microti infection in a biological sample, comprising:
(a) contacting the biological sample with a first binding agent which is capable of binding to a polypeptide according to any one of claims 2, 6 and 8, and a second binding agent which is capable of binding to an antigenic epitope according to any one of claims 3 and 7; and (b) detecting in the sample a polypeptide that binds to the first binding agent or an antigenic epitope that binds to the second binding agent, thereby detecting B. microti infection in the biological sample.
- 30. The method of claim 29 wherein the binding agent is a monoclonal antibody.
- 31. The method of claim 29 wherein the binding agent is a polyclonal antibody.
- 32. A diagnostic kit comprising
(a) at least one polypeptide according to any one of claims 2, 6 and 8; (b) a detection reagent.
- 33. A diagnostic kit comprising:
(a) at least one antigenic epitope according to any one of claims 3 and 7; and (b) a detection reagent.
- 34. A diagnostic kit comprising:
(a) at least one antigenic epitope according to any one of claims 3 and 7; (b) at least one polypeptide according to any one of claims 2, 6 and 8; and (c) a detection reagent.
- 35. A fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 85, 87, 144 and 211.
- 36. A diagnostic kit comprising:
(a) at least one fusion protein according to any one of claims 13, 16 and 35; and (b) a detection reagent.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to U.S. patent application Ser. No. 09/794,764, filed Feb. 26, 2001 (pending); U.S. patent application Ser. No. 09/737,178, filed Dec. 13, 2000 (pending); U.S. patent application Ser. No. 09/685,436, filed Oct. 10, 2000 (pending); U.S. patent application Ser. No. 09/656,688, filed Sep. 7, 2000 (pending); U.S. application Ser. No. 09/605,724, filed Jun. 27, 2000 (pending); U.S. application Ser. No. 09/569,098, filed May 10, 2000 (pending); U.S. application Ser. No. 09/528,784, filed Mar. 17, 2000 (pending); U.S. application Ser. No. 09/286,488, filed Apr. 5, 1999 (pending); U.S. application Ser. No. 08/990,571, filed Dec. 11, 1997 (allowed); U.S. application Ser. No. 08/845,258, filed Apr. 24, 1997 (allowed); U.S. application Ser. No. 08/723,142, filed Oct. 1, 1996 (pending); each a continuation-in-part of the previous application and all incorporated herein by reference.
Continuation in Parts (11)
|
Number |
Date |
Country |
Parent |
09794764 |
Feb 2001 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09737178 |
Dec 2000 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09685436 |
Oct 2000 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09656688 |
Sep 2000 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09605724 |
Jun 2000 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09569098 |
May 2000 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09528784 |
Mar 2000 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
09286488 |
Apr 1999 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
08990571 |
Dec 1997 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
08845258 |
Apr 1997 |
US |
Child |
09853079 |
May 2001 |
US |
Parent |
08723142 |
Oct 1996 |
US |
Child |
09853079 |
May 2001 |
US |